| Website | relypsa.com |
| Category | BioTech |
| PR@Relypsa.com | |
| Employees | |
| Founded | 10/07 |
| TOTAL | $183M |
| FUNDING TOTAL | $183M |
| Series A, 10/07 5AM Ventures New Leaf Venture Partners Sprout Group Delphi Ventures CMEA Ventures Mediphase Venture Partners | $33M |
| Series B, 9/10 OrbiMed Advisors New Leaf Venture Partners 5AM Ventures Delphi Ventures Sprout Group Mediphase Venture Partners | $70M |
| Series C, 8/12 | $80M |
Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa’s lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.
